Debbie Rigby takes a look at the latest research pertinent to community pharmacy
In this double-blind trial, liraglutide, an analogue of human glucagon like peptide 1 (GLP-1), showed a lower rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus compared to placebo.
New Engl J Med 2016. Published online June 14, 2016
A systematic review and meta-analysis of 62 studies has concluded that phytoestrogen (soy isoflavone) supplementations are associated with modest reductions in the frequency of hot flashes and vaginal dryness but no significant reduction in night sweats. There was no significant association between Chinese medicinal herbs or black cohosh (Cimicifuga racemosa or Actaea racemosa) supplementation and menopausal symptoms.
A large multicentre double-blind trial has found that ticagrelor (90mg twice daily) is not superior to aspirin (100mg once daily) in reducing the rate of stroke, myocardial infarction, or death at 90 days in patients with acute ischemic stroke or transient ischemic attack. Major bleeding occurred in 0.5% of patients treated with ticagrelor and in 0.6% of patients treated with aspirin, intracranial hemorrhage in 0.2% and 0.3%, respectively, and fatal bleeding in 0.1% and 0.1%.
N Engl J Med 2016; 375:35-43.
A prospective study of 1418 patients, aged 70 and older, admitted to 11 hospitals across Australia has concluded that patient frailty is a better signal for medication review than polypharmacy. Assessing the frailty status of patients better appraised risk of adverse health outcomes including falls, delirium, functional and cognitive decline, discharge to a higher level of care and in-hospital mortality.
Journal of the American Medical Directors Association 2016